COSMO PHARMACEUTICALS NV (C43.DE) Stock Analyst Earnings Estimates
FRA:C43 - Deutsche Boerse Ag - NL0011832936 - Common Stock - Currency: EUR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 65.074M 6.77% | 102.089M 56.88% | 92.78M -9.12% | 271.61M 192.75% | 253.7M -6.59% | 226.23M -10.83% | 397.13M 75.54% | 453.91M 14.30% | 814.37M 79.41% | 670.34M -17.69% | 539.3M -19.55% | 457M -15.26% | |
| EBITDA YoY % growth | 18.47M 106.60% | 41.913M 126.92% | 20.407M -51.31% | 179.13M 777.79% | 139.8M -21.96% | 100.08M -28.41% | 389.21M 288.90% | 458.08M 17.69% | 620.52M 35.46% | 480.82M -22.51% | 367.12M -23.65% | 292.39M -20.36% | |
| EBIT YoY % growth | 11.101M 282.13% | 28.057M 152.74% | 6.146M -78.09% | 164.74M 2,580.44% | 127.46M -22.63% | 82.069M -35.61% | 241.87M 194.72% | 278.64M 15.20% | 603.2M 116.48% | 463.5M -23.16% | 348.71M -24.77% | 273.98M -21.43% | |
| Operating Margin | 17.06% | 27.48% | 6.62% | 60.65% | 50.24% | 36.28% | 60.90% | 61.39% | 74.07% | 69.14% | 64.66% | 59.95% | |
| EPS YoY % growth | N/A 248.52% | 1.05 29.36% | N/A 322.00% | 7.81 76.44% | 5.90 -24.45% | 3.91 -33.79% | 12.03 208.06% | 13.83 14.96% | 30.55 120.82% | 23.72 -22.37% | 18.99 -19.91% | 16.41 -13.63% |
All data in EUR
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | 2.71 177.08% |
| Revenue Q2Q % growth | 123.42M 151.27% |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | 77.316M 8,013.61% |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 4.72 5,028.26% | 4.35 | 0.37 | 8.58% |
| Q4 2023 Q2Q % growth | 70.89% | 0.98 | % | |
| Q2 2023 Q2Q % growth | 0.09 -80.67% | 0.06 | 0.03 | 50.33% |
| Q4 2022 Q2Q % growth | 0.57 -29.78% | 0.91 | -0.33 | -36.88% |
| Q2 2022 Q2Q % growth | 0.48 219.00% | -0.06 | 0.54 | 877.78% |
| Q4 2021 Q2Q % growth | 342.86% | 0.82 | % | |
| Q2 2021 Q2Q % growth | -0.40 -90.48% | -0.41 | 0.01 | 1.96% |
| Q4 2020 Q2Q % growth | -0.34 -28.24% | -0.71 | 0.38 | 52.94% |
| Q2 2020 Q2Q % growth | -0.21 85.07% | -0.20 | -0.01 | -2.94% |
| Q4 2019 Q2Q % growth | -0.26 | -0.43 | 0.17 | 38.84% |
| Q2 2019 Q2Q % growth | -1.41 | -1.12 | -0.28 | -25.40% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 136.237M 212.03% | 145.86M | -9.623M | -6.60% |
| Q4 2023 Q2Q % growth | 49.119M -18.92% | 69.36M | -20.241M | -29.18% |
| Q2 2023 Q2Q % growth | 43.661M 5.18% | 45.9M | -2.239M | -4.88% |
| Q4 2022 Q2Q % growth | 60.578M 65.27% | 59.16M | 1.418M | 2.40% |
| Q2 2022 Q2Q % growth | 41.511M 46.06% | 39.78M | 1.731M | 4.35% |
| Q4 2021 Q2Q % growth | 36.654M 4.53% | 33.66M | 2.994M | 8.89% |
| Q2 2021 Q2Q % growth | 28.42M 9.80% | 29.58M | -1.16M | -3.92% |
| Q4 2020 Q2Q % growth | 35.066M -14.45% | 27.405M | 7.661M | 27.95% |
| Q2 2020 Q2Q % growth | 25.883M 20.35% | 25.5M | 383K | 1.50% |
| Q4 2019 Q2Q % growth | 40.988M | 23.46M | 17.528M | 74.71% |
| Q2 2019 Q2Q % growth | 21.507M | 27.54M | -6.033M | -21.91% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | -2.66% |
| Revenue | N/A | N/A | 0.7% | 0.45% |